Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 28;15(4):e12482.
doi: 10.1002/dad2.12482. eCollection 2023 Oct-Dec.

Early-onset Alzheimer's disease explained by polygenic risk of late-onset disease?

Affiliations

Early-onset Alzheimer's disease explained by polygenic risk of late-onset disease?

William G Mantyh et al. Alzheimers Dement (Amst). .

Abstract

Early-onset Alzheimer's disease (AD) is highly heritable, yet only 10% of cases are associated with known pathogenic mutations. For early-onset AD patients without an identified autosomal dominant cause, we hypothesized that their early-onset disease reflects further enrichment of the common risk-conferring single nucleotide polymorphisms associated with late-onset AD. We applied a previously validated polygenic hazard score for late-onset AD to 193 consecutive patients diagnosed at our tertiary dementia referral center with symptomatic early-onset AD. For comparison, we included 179 participants with late-onset AD and 70 healthy controls. Polygenic hazard scores were similar in early- versus late-onset AD. The polygenic hazard score was not associated with age-of-onset or disease biomarkers within early-onset AD. Early-onset AD does not represent an extreme enrichment of the common single nucleotide polymorphisms associated with late-onset AD. Further exploration of novel genetic risk factors of this highly heritable disease is warranted.Highlights: There is a unique genetic architecture of early- versus late-onset Alzheimer's disease (AD).Late-onset AD polygenic risk is not an explanation for early-onset AD.Polygenic risk of late-onset AD does not predict early-onset AD biology.Unique genetic architecture of early- versus late-onset AD parallels AD heterogeneity.

Keywords: age of onset; biomarkers; early‐onset Alzheimer's disease; late‐onset Alzheimer's disease; polygenic risk.

PubMed Disclaimer

Conflict of interest statement

Dr W.M. reports consulting fees from Genentech/Roche and research support from the NIH, the American Academy of Neurology, American Brain Foundation, Alzheimer's Association, Wallin Foundation, and Fesler‐Lampert Foundation. Dr N.C. reports receiving consulting fees from Caraway Therapeutics and research support from the NIH. Mr J.T. reports no disclosures. Dr E.G. reports no disclosures. Dr I.B. reports no disclosures. Dr L.B. reports no disclosures. Ms A.A. reports no disclosures. Dr D.S. reports no disclosures. Dr R.L.J. reports no disclosures. Dr L.I. reports no disclosures. Ms K.C. reports no disclosures. Ms L.E. reports no disclosures. Ms A.S. reports no disclosures. Ms H.G. reports no disclosures. Dr I.A. reports no disclosures. Dr Z.M. reports no disclosures. Dr M.G.‐T. reports no disclosures. Dr B.M. reports no disclosures. Dr R.D. is posthumously a co‐author. Dr J.K. reports royalties from Pearson, Inc. and being on an advisory board for Biogen. Dr G.R. consulting fees from Eli Lilly, GE Healthcare, Genentech, Johnson & Johnson, and Roche and research support from the NIH, Alzheimer's Association, American College of Radiology, Rainwater Charitable Foundation, Avid Radiopharmaceuticals, GE Healthcare, Genentech, and Life Molecular Imaging. Dr J.Y. reports no disclosures. The authors have no conflicts of interest listed in the supporting information.

Figures

FIGURE 1
FIGURE 1
Regression of age of onset versus polygenic hazard score in early‐onset versus late‐onset Alzheimer's disease. EOAD, early‐onset Alzheimer's disease; LOAD, late‐onset Alzheimer's disease; PHS, polygenic hazard score (Desikan et al. 7 )

Similar articles

Cited by

References

    1. Ridge PG, Hoyt KB, Boehme K, et al. Assessment of the genetic variance of late‐onset Alzheimer's disease. Neurobiol Aging. 2016;41:200.e13‐200.e20. doi:10.1016/J.NEUROBIOLAGING.2016.02.024 - DOI - PMC - PubMed
    1. Goate A, Chartier‐Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349(6311):704‐706. doi:10.1038/349704a0. 1991 3496311. - DOI - PubMed
    1. Sherrington R, Leresque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early‐onset familial Alzheimer's disease. Nature. 1995;375(June):754‐760. - PubMed
    1. Rogaev EI, Sherrlngton R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations In a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376(August):775‐778. - PubMed
    1. Lambert JC, Ibrahim‐Verbaas CA, Harold D, et al. Meta‐analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452‐1458. doi:10.1038/ng.2802 - DOI - PMC - PubMed

Grants and funding